Tetrapyrroles and derivatives
Abcam Tetrahydrouridine, cytidine deaminase inhibitor, 25MG
MW 248.23 Da, Purity >80%. Competitive cytidine deaminase inhibitor (IC₅₀= 152 μM). Modulates antiproliferative effects. Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam QNZ, NF-kB inhibitor, 1MG
MW 358.4 Da, Purity >98%. Potent, selective NF-kB inhibitor (IC₅₀ = 11 nM). Inhibits LPS-induced TNFα production (IC₅₀ = 7 nM). Reduces edema in inflammation in vivo..
The product is subject to the following: Abcam Restricted Use Statement
Abcam beta-Amyloid Peptide (1-42) (rat/mouse), 500UG
MW 4418 Da. beta-Amyloid Peptide (1-42) (rat/mouse). Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CL-316243 disodium salt, adrenergic-beta3 receptor agonist, 25MG
MW 465.8 Da, Purity >99%. Selective adrenergic-β3 receptor agonist. Induces adipose tissue remodelling in rat. Hypoglycemic agent. Active *in vivo* and *in vitro*.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Nocodazole, Microtubule inhibitor, 25MG
MW 301.32 Da, Purity >98%. Microtubule inhibitor. Rapidly depolymerises microtubules in vivo and inhibits tubulin polymerisation in vitro. Inhibits mitosis. Also reduces stem cell pluripotency factors Oct 4 and Nanog.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Undecylprodigiosin, Apoptotic and anticancer agent, 250UG
MW 393.6 Da, Purity >93%. Apoptotic and anticancer agent. Selectively induces p53-independant apoptosis in cancer cells. Induces G2/M cell cycle arrest and shows antiproliferative effects. Shows antimalarial and antibactieral effects in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ibotenic acid, e x citoto x ic agonist, 25MG
MW 158.11 Da, Purity >98%. Neuroexcitatory amino acid originally isolated from Amanita species. Neurotoxin often used to model cognitive dysfunctions. NMDA and metabotropic receptor agonist.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 206553 hydrochloride, 5-HT2B and 5-HT2C receptor antagonist, 10MG
MW 292.33 Da, Purity >99%. Potent and selective 5-HT2B and 5-HT2C serotonin receptor antagonist (pKi values are 7.92 (5-HT2C), 5.78 (5-HT2A), 7.65 (5-HT2B), 1A), 1D), 1E) and 1F). Centrally active following oral administration.
The product is subject to the following: Abcam Restricted Use Statement
Abcam x E-991 dihydrochloride, KCNQ channel blocker; blocks M current, 50MG
MW 449.4 Da, Purity >99%. Potent and selective blocker of KCNQ voltage-gated potassium channels. Blocks M current. (IC₅₀ values are 0.98 μM (M-current), 0.71 μM (KCNQ 2), 0.75 μM (KCNQX 1), >100 μM (Kv1.2) and >43 μM (Kv4.3). Potent pulmonary vasoconstrictor. Cognitive enhancer following oral administration in vivo.
The product is subject to the following: Abcam Restricted Use Statement